Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2023-08-24 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
2023年半年度财务报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "赛隆药业集团股份有限公司 2023 年半年度财务报告（未经审计）" which translates to "Sailong Pharmaceutical Group Co., Ltd. 2023 Semi-Annual Financial Report (Unaudited)". It contains detailed financial statements such as consolidated and company balance sheets, profit statements, cash flow statements, changes in shareholders' equity, and extensive notes on accounting policies and financial instruments. The document covers the half-year period ending June 30, 2023, and includes substantive financial data and analysis. The length is about 15,000 characters, indicating a full report rather than a brief announcement. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-24 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 赛隆药业集团股份有限公司 regarding their 11th meeting of the 3rd Supervisory Board. It includes details about the meeting's convening, attendance, and resolutions passed, such as approval of the 2023 semi-annual report, reappointment of the audit firm, and a shareholder return plan for 2023-2025. The document references the actual 2023 semi-annual report and other announcements published separately on the cninfo website, indicating this document itself is a meeting resolution announcement rather than the report or detailed financial data. The document length is short (1238 characters), and it mainly announces decisions and approvals, consistent with a Regulatory Filing (RNS) rather than a full Interim Report (IR) or Annual Report (10-K).
2023-08-24 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 15th meeting of the 3rd Board of Directors of Sailong Pharmaceutical Group Co., Ltd. It details the meeting's convening, attendance, and voting results on various agenda items, including approval of the 2023 semi-annual report, reappointment of the audit firm, shareholder return plans, and calling a shareholders' meeting. The document does not contain the actual semi-annual report or financial data but references where these can be found. It is a board meeting resolution announcement, not a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is an announcement of board decisions rather than the report itself, so it is not an Interim/Quarterly Report (IR) or Annual Report (10-K).
2023-08-24 Chinese
关于持股5%以上股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the partial release of pledged shares by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, the number of shares released from pledge, pledge dates, and the current status of pledged shares. There is no financial statement, management discussion, or report content. The document is short (1304 characters) and serves as a regulatory disclosure about share pledge status, which fits the category of Major Shareholding Notification (MRQ) or possibly Regulatory Filings (RNS). However, since it specifically concerns a shareholder holding more than 5% and changes in pledged shares, it aligns best with Major Shareholding Notification (MRQ).
2023-08-21 Chinese
关于股价异动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations for the company 赛隆药业集团股份有限公司. It includes explanations about the stock price movement, confirmation of no undisclosed material information, and risk warnings. It references a previously disclosed half-year performance forecast and states that the detailed financial data will be in the company's half-year report. The document is short (1239 characters) and serves as a regulatory disclosure about stock price anomalies rather than a financial report or earnings release. It does not contain financial statements or detailed financial data. Therefore, it fits best as a Regulatory Filing (RNS) which covers miscellaneous regulatory announcements that do not fit other categories.
2023-08-15 Chinese
关于持股5%以上股东股份减持计划时间过半的进展公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the progress of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the reduction method, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data but is focused on shareholding changes by a major shareholder. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2023-07-20 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.